Literature DB >> 25900730

Synthesis and characterization of lanthanum phosphate nanoparticles as carriers for (223)Ra and (225)Ra for targeted alpha therapy.

J V Rojas1, J D Woodward2, N Chen3, A J Rondinone2, C H Castano4, S Mirzadeh5.   

Abstract

INTRODUCTION: Targeted alpha therapy (TAT) has the potential for killing micro-metastases with minimum collateral damage to surrounding healthy tissue. In-vivo generator radionuclides, such as(223)Ra, (225)Ra, and (225)Ac, are of special interest for radiotherapeutic applications as they emit multiple α-particles during their decay. Utilizing appropriate carriers capable of retaining both the parent radioisotope as well as daughter products is important for the effective delivery of the radioisotope to the tumor site while mitigating global in vivo radiotoxicity. In this work, LaPO4 core and core+2 shells nanoparticles (NPs) (NPs with 2 layers of cold LaPO4 deposited on the core surfaces) were synthesized containing either (223)Ra or(225)Ra/(225)Ac, and the retention of the parents and daughters within the NPs in vitro was investigated.
METHODS: Core LaPO4 NPs were synthesized in aqueous solution by reacting 1 equivalent of La(NO3)3, along with few microcuries of either (223)Ra or (225)Ra/(225)Ac, with 1 equivalent of sodium tripolyphosphate (TPP) under moderate heating and purified by membrane dialysis. Core-shell NPs were also synthesized with one (core+1 shell) and two (core+2 shells) cold LaPO4 layers deposited onto the radioactive cores. The NPs were then characterized by transmission electron microscopy (TEM) and powder x-ray diffraction (XRD). Identification and quantification of radioactive parents and daughters released from the NPs in vitro were investigated using gamma-ray spectroscopy.
RESULTS: XRD and TEM analysis revealed that the NPs crystallized in the rhabdophane phase with mean diameters of 3.4 and 6.3nm for core and core+2 shells, respectively. The core LaPO4 NPs retained up to 88% of (223)Ra over 35days. However, in the core+2 shells NPs, the retention of (223)Ra and its daughter, (211)Pb, was improved to >99.9% over 27days. Additionally, the retention of (225)Ra/(225)Ac parents was >99.98% and ~80% for the (221)Fr and (213)Bi daughters over 35days for the core+2 shells NPs.
CONCLUSIONS: The in vitro retention of both parents and daughters results suggests that LaPO4 NPs are potentially effective carriers of radium isotopes.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Actinium-225; Lanthanum phosphate; Radioactive nanoparticles; Radium-223; Radium-225; Targeted alpha therapy; Targeted radioimmunotherapy; in-vitro retention; in-vivo generators

Mesh:

Substances:

Year:  2015        PMID: 25900730     DOI: 10.1016/j.nucmedbio.2015.03.007

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  5 in total

1.  Improved Formulation of 224Ra-Labeled Calcium Carbonate Microparticles by Surface Layer Encapsulation and Addition of EDTMP.

Authors:  Ruth Gong Li; Kim Lindland; Sandra Karen Tonstad; Tina Bjørnlund Bønsdorff; Asta Juzeniene; Sara Westrøm; Roy Hartvig Larsen
Journal:  Pharmaceutics       Date:  2021-04-29       Impact factor: 6.321

2.  Functionalized TiO2 nanoparticles labelled with 225Ac for targeted alpha radionuclide therapy.

Authors:  Edyta Cędrowska; Marek Pruszynski; Agnieszka Majkowska-Pilip; Sylwia Męczyńska-Wielgosz; Frank Bruchertseifer; Alfred Morgenstern; Aleksander Bilewicz
Journal:  J Nanopart Res       Date:  2018-03-20       Impact factor: 2.253

Review 3.  Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators.

Authors:  Ján Kozempel; Olga Mokhodoeva; Martin Vlk
Journal:  Molecules       Date:  2018-03-05       Impact factor: 4.411

4.  Lanthanum phosphate/chitosan scaffolds enhance cytocompatibility and osteogenic efficiency via the Wnt/β-catenin pathway.

Authors:  Haoran Hu; Peipei Zhao; Jiayu Liu; Qinfei Ke; Changqing Zhang; Yaping Guo; Hao Ding
Journal:  J Nanobiotechnology       Date:  2018-11-29       Impact factor: 10.435

5.  Ra-224 labeling of calcium carbonate microparticles for internal α-therapy: Preparation, stability, and biodistribution in mice.

Authors:  Sara Westrøm; Marion Malenge; Ida Sofie Jorstad; Elisa Napoli; Øyvind S Bruland; Tina B Bønsdorff; Roy H Larsen
Journal:  J Labelled Comp Radiopharm       Date:  2018-03-12       Impact factor: 1.921

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.